Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CSL Limited

Market Cap 36.8B 31.79B 29.29B 27.42B 51.38B 3,498B 52.18B 346B 135B 1,703B 138B 135B 5,895B P/E Ratio 2026 *
-48.7x
P/E Ratio 2027 * 24.5x
Enterprise Value 45.64B 39.42B 36.32B 34B 63.72B 4,338B 64.7B 429B 167B 2,111B 171B 168B 7,311B EV / Sales 2026 *
2.97x
EV / Sales 2027 * 2.86x
Free-Float
99.3%
Yield 2026 *
3.76%
Yield 2027 * 3.87%
1 day+0.68%
1 week+7.19%
Current month+7.19%
1 month+8.76%
3 months-25.50%
6 months-40.99%
Current year-37.39%
1 week 13.8
Extreme 13.8
14.9
1 month 12.7
Extreme 12.7
14.9
Current year 12.7
Extreme 12.7
43.4
1 year 12.7
Extreme 12.7
43.4
3 years 12.7
Extreme 12.7
47.5
5 years 12.7
Extreme 12.7
51
10 years 12.7
Extreme 12.7
52.5
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Tech/Sci/R&D Officer 64 2020-09-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2013-08-13
Director/Board Member 68 2016-02-15
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+7.19% - - 36.8B
+0.11%-3.67%+15.66%-20.23% 62.28B
+1.44%+5.33%+68.19%+222.27% 60.59B
+0.70%+29.50%+29.50%+29.50% 39.55B
+0.05%+2.41%+53.12%-34.32% 29.53B
+0.65%+6.01%+60.19%+75.19% 21.68B
+0.54%+5.21%+87.14%-61.00% 19.8B
+4.80%-0.20%-5.27%+115.05% 16.96B
+0.18%-1.66%+54.11%+100.91% 16.16B
+0.55%+9.84%+145.12%+240.77% 13.13B
Average +0.97%+3.11%+56.42%+74.24% 31.08B
Weighted average by Cap. +0.84%+2.41%+48.50%+69.82%

Financials

2026 *2027 *
Net sales 15.38B 13.28B 12.24B 11.46B 21.47B 1,462B 21.81B 145B 56.36B 712B 57.72B 56.49B 2,464B 15.68B 13.55B 12.48B 11.69B 21.9B 1,491B 22.24B 147B 57.47B 726B 58.86B 57.61B 2,513B
Net income -895M -773M -712M -667M -1.25B -85.04B -1.27B -8.41B -3.28B -41.39B -3.36B -3.29B -143B 1.22B 1.06B 975M 912M 1.71B 116B 1.74B 11.51B 4.49B 56.65B 4.6B 4.5B 196B
Net Debt 8.84B 7.63B 7.03B 6.58B 12.34B 840B 12.53B 83.04B 32.38B 409B 33.16B 32.46B 1,415B 8.08B 6.98B 6.43B 6.02B 11.29B 768B 11.46B 75.97B 29.62B 374B 30.34B 29.69B 1,295B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change
26-06-12 14.90 +0.68%
26-06-11 14.80 +4.96%
26-06-10 14.10 -0.70%
26-06-09 14.20 +2.90%
26-06-08 13.80 -0.72%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
75.83USD
Average target price
98.02USD
Spread / Average Target
+29.27%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!